
Rimona S Weil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4833788/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Relating Introspective Accuracy to Individual Differences in Brain Structure. Science, 2010, 329, 1541-1543.	12.6	677
2	Visual dysfunction in Parkinson's disease. Brain, 2016, 139, 2827-2843.	7.6	320
3	The development of metacognitive ability in adolescence. Consciousness and Cognition, 2013, 22, 264-271.	1.5	219
4	Relating inter-individual differences in metacognitive performance on different perceptual tasks. Consciousness and Cognition, 2011, 20, 1787-1792.	1.5	128
5	Brain iron deposition is linked with cognitive severity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 418-425.	1.9	121
6	Features of <i>GBA</i> -associated Parkinson's disease at presentation in the UK <i>Tracking Parkinson's</i> study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	1.9	103
7	Hearing and dementia: from ears to brain. Brain, 2021, 144, 391-401.	7.6	92
8	Rewarding Feedback After Correct Visual Discriminations Has Both General and Specific Influences on Visual Cortex. Journal of Neurophysiology, 2010, 104, 1746-1757.	1.8	80
9	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 512-519.	1.9	75
10	Neuroimaging in Parkinson's disease dementia: connecting the dots. Brain Communications, 2019, 1, fcz006.	3.3	62
11	Mild Cognitive Impairment in Parkinson's Disease—What Is It?. Current Neurology and Neuroscience Reports, 2018, 18, 17.	4.2	57
12	Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction. Neurology, 2020, 94, e1525-e1538.	1.1	51
13	Sequence of clinical and neurodegeneration events in Parkinson's disease progression. Brain, 2021, 144, 975-988.	7.6	49
14	Can neuroimaging predict dementia in Parkinson's disease?. Brain, 2018, 141, 2545-2560.	7.6	46
15	Increased weighting on prior knowledge in Lewy body-associated visual hallucinations. Brain Communications, 2019, 1, fcz007.	3.3	45
16	Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. Brain, 2021, 144, 1787-1798.	7.6	44
17	Visual tests predict dementia risk in Parkinson disease. Neurology: Clinical Practice, 2020, 10, 29-39.	1.6	41
18	A new taxonomy for perceptual filling-in. Brain Research Reviews, 2011, 67, 40-55.	9.0	37

RIMONA S WEIL

#	Article	IF	CITATIONS
19	Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson's disease. Communications Biology, 2021, 4, 86.	4.4	37
20	Neural correlates of perceptual filling-in of an artificial scotoma in humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5211-5216.	7.1	35
21	Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	1.6	35
22	Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease. Movement Disorders, 2021, 36, 1191-1202.	3.9	32
23	Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease. Brain, 2020, 143, 3435-3448.	7.6	31
24	Air swallowing as a tic. Journal of Psychosomatic Research, 2008, 65, 497-500.	2.6	29
25	The Catsâ€andâ€Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease. Movement Disorders, 2017, 32, 1789-1790.	3.9	26
26	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. Sensors, 2021, 21, 5437.	3.8	26
27	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
28	Neural correlates of perceptual completion of an artificial scotoma in human visual cortex measured using functional MRI. NeuroImage, 2008, 42, 1519-1528.	4.2	23
29	Decoding the neural correlates of consciousness. Current Opinion in Neurology, 2010, 23, 649-655.	3.6	23
30	Optimal dose of stereotactic radiosurgery for acoustic neuromas: a systematic review. British Journal of Neurosurgery, 2006, 20, 195-202.	0.8	21
31	Neural correlates of early cognitive dysfunction in Parkinson's disease. Annals of Clinical and Translational Neurology, 2019, 6, 902-912.	3.7	17
32	Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 169-179.	1.9	17
33	REM sleep behaviour disorder: an early window for prevention in neurodegeneration?. Brain, 2019, 142, 498-501.	7.6	16
34	Hallucinations in Parkinson's disease: new insights into mechanisms and treatments. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 20-22.	0.1	15
35	Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations. Nature Communications, 2022, 13, 519.	12.8	15
36	Disrupted reward processing in Parkinson's disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 555-562.	1.9	15

RIMONA S WEIL

#	Article	IF	CITATIONS
37	Suspecting dementia: canaries, chameleons and zebras. Practical Neurology, 2021, 21, 300-312.	1.1	13
38	Computer-vision based method for quantifying rising from chair in Parkinson's disease patients. Intelligence-based Medicine, 2022, 6, 100046.	2.4	13
39	Advances in neuroimaging to support translational medicine in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 263-270.	1.9	12
40	Neural correlates of hemianopic completion across the vertical meridian. Neuropsychologia, 2009, 47, 457-464.	1.6	11
41	Opposite effects of perceptual and working memory load on perceptual filling-in of an artificial scotoma. Cognitive Neuroscience, 2012, 3, 36-44.	1.4	10
42	Selective 5HT3 antagonists and sensory processing: a systematic review. Neuropsychopharmacology, 2022, 47, 880-890.	5.4	10
43	Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. Neuro-Oncology Practice, 2020, 7, 196-201.	1.6	9
44	Processing of Degraded Speech in Brain Disorders. Brain Sciences, 2021, 11, 394.	2.3	9
45	Dementia risk in Parkinson's disease is associated with interhemispheric connectivity loss and determined by regional gene expression. NeuroImage: Clinical, 2020, 28, 102470.	2.7	7
46	Thalamic white matter macrostructure and subnuclei volumes in Parkinson's disease depression. Npj Parkinson's Disease, 2022, 8, 2.	5.3	7
47	Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone. Movement Disorders Clinical Practice, 2020, 7, 955-960.	1.5	6
48	Visual hallucinations. Practical Neurology, 2021, 21, 327-332.	1.1	5
49	Evaluation of START (STrAtegies for RelaTives) adapted for carers of people with Lewy body dementia. Future Healthcare Journal, 2020, 7, e27-e29.	1.4	3
50	Flickering Stimuli Do Not Reliably Induce Visual Hallucinations in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 631-635.	2.8	2
51	Subarachnoid haemorrhage as the presenting feature of lumbar spinal arteriovenous malformation. Practical Neurology, 2013, 13, 319-321.	1.1	1
52	Visual Dysfunction and Parkinson's Disease. Movement Disorders, 2020, 35, 1499-1501.	3.9	1
53	Reply: MRI findings of visual system alterations in Parkinson's disease. Brain, 2017, 140, e70-e70.	7.6	0
54	PO086â€European registry of corticobasal degeneration a prospect sister study: recruitment of patients with corticobasal syndrome via the bnsu. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A34.2-A34.	1.9	0

#	Article	IF	CITATIONS
55	Beyond dopamine: Further evidence of cholinergic dysfunction in Parkinson's disease (Commentary on) Tj ETQq1	1 _{2.6} 78431	.4rgBT /Ove
56	Fixelâ€based analysis of the effect of amyloid beta on white matter tracts in neurologically normal 70 year olds. Alzheimer's and Dementia, 2021, 17, .	0.8	0